Keywords
Last Name
Institution

CHRISTOPHER J LOGOTHETIS

TitleProfessor
InstitutionMD Anderson
DepartmentGenitourinary Medical Oncology
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol. 2018 May; 73(5):715-723. PMID: 29258679.
      View in: PubMed
    2. Lin SC, Lee YC, Yu G, Cheng CJ, Zhou X, Chu K, Murshed M, Le NT, Baseler L, Abe JI, Fujiwara K, deCrombrugghe B, Logothetis CJ, Gallick GE, Yu-Lee LY, Maity SN, Lin SH. Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate Cancer. Dev Cell. 2017 Jun 05; 41(5):467-480.e3. PMID: 28586644.
      View in: PubMed
    3. Zhang X, Li B, Rezaeian AH, Xu X, Chou PC, Jin G, Han F, Pan BS, Wang CY, Long J, Zhang A, Huang CY, Tsai FJ, Tsai CH, Logothetis C, Lin HK. H3 ubiquitination by NEDD4 regulates H3 acetylation and tumorigenesis. Nat Commun. 2017 Mar 16; 8:14799. PMID: 28300060.
      View in: PubMed
    4. Tu H, Gu J, Meng QH, Kim J, Strom S, Davis JW, He Y, Wagar EA, Thompson TC, Logothetis CJ, Wu X. Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncol Lett. 2017 Mar; 13(3):1949-1957. PMID: 28454349.
      View in: PubMed
    5. Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Stephenson A, Li Ning Tapia EM, Efstathiou E, Wang X, Do KA, Lee JJ, Gorlov IP, Vornik LA, Hoque AM, Prokhorova IN, Parnes HL, Lippman SM, Thompson IM, Brown PH, Logothetis CJ, Troncoso P. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine. 2016 May; 7:85-93. PMID: 27322462; PMCID: PMC4909608.
    6. Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karam JA, Ward JF, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, Yeung SC, Lin SH, Logothetis CJ, Pisters LL. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. 2016 Jun 15; 122(12):1836-43. PMID: 27018785.
      View in: PubMed
    7. Paranjape AN, Soundararajan R, Werden SJ, Joseph R, Taube JH, Liu H, Rodriguez-Canales J, Sphyris N, Wistuba I, Miura N, Dhillon J, Mahajan N, Mahajan K, Chang JT, Ittmann M, Maity SN, Logothetis C, Tang DG, Mani SA. Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties. Oncogene. 2016 Nov 17; 35(46):5963-5976. PMID: 26804168.
      View in: PubMed
    8. Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S, Fang Z, Zhao K, Konaparthi R, Hua S, Zhang J, Li-Ning-Tapia EM, Kapoor A, Wu CJ, Patel NB, Guo Z, Ramamoorthy V, Tieu TN, Heffernan T, Zhao D, Shang X, Khadka S, Hou P, Hu B, Jin EJ, Yao W, Pan X, Ding Z, Shi Y, Li L, Chang Q, Troncoso P, Logothetis CJ, McArthur MJ, Chin L, Wang YA, DePinho RA. Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. Cancer Discov. 2016 Jan; 6(1):80-95. PMID: 26701088.
      View in: PubMed
    9. Tu H, Gu J, Meng QH, Kim J, Davis JW, He Y, Wagar EA, Thompson TC, Logothetis CJ, Wu X. Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancer. Oncotarget. 2015 Dec 8; 6(39):41988-96. PMID: 26515605.
      View in: PubMed
    10. Lee YC, Lin SC, Yu G, Cheng CJ, Liu B, Liu HC, Hawke DH, Parikh NU, Varkaris A, Corn P, Logothetis C, Satcher RL, Yu-Lee LY, Gallick GE, Lin SH. Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. Cancer Res. 2015 Nov 15; 75(22):4949-59. PMID: 26530902.
      View in: PubMed
    11. Varkaris A, Corn PG, Parikh NU, Efstathiou E, Song JH, Lee YC, Aparicio A, Hoang AG, Gaur S, Thorpe L, Maity SN, Bar Eli M, Czerniak BA, Shao Y, Alauddin M, Lin SH, Logothetis CJ, Gallick GE. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res. 2016 Jan 1; 22(1):107-21. PMID: 26272062.
      View in: PubMed
    12. Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR, Sonpavde G, Sartor O, Saad F. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. Eur Urol. 2015 Nov; 68(5):850-8. PMID: 26153564.
      View in: PubMed
    13. Davis JW, Ward JF, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 Jul; 118(1):68-76. PMID: 26059275; PMCID: PMC4808616 [Available on 07/01/17].
    14. Salameh A, Lee AK, Cardó-Vila M, Nunes DN, Efstathiou E, Staquicini FI, Dobroff AS, Marchiò S, Navone NM, Hosoya H, Lauer RC, Wen S, Salmeron CC, Hoang A, Newsham I, Lima LA, Carraro DM, Oliviero S, Kolonin MG, Sidman RL, Do KA, Troncoso P, Logothetis CJ, Brentani RR, Calin GA, Cavenee WK, Dias-Neto E, Pasqualini R, Arap W. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proc Natl Acad Sci U S A. 2015 Jul 7; 112(27):8403-8. PMID: 26080435.
      View in: PubMed
    15. Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015 Aug; 26(8):1589-604. PMID: 26041764.
      View in: PubMed
    16. Pagliaro LC, Tannir NM, Tu SM, Logothetis CJ. Management of Clinical Stage I Testicular Cancer: How Should We Define Success? J Clin Oncol. 2015 Jul 10; 33(20):2321-2. PMID: 26033805.
      View in: PubMed
    17. Zurita AJ, Pisters LL, Wang X, Troncoso P, Dieringer P, Ward JF, Davis JW, Pettaway CA, Logothetis CJ, Pagliaro LC. Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2015 Sep; 18(3):276-80. PMID: 26171883.
      View in: PubMed
    18. Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol. 2015 Oct; 68(4):570-7. PMID: 25985882.
      View in: PubMed
    19. Parker PA, Davis JW, Latini DM, Baum G, Wang X, Ward JF, Kuban D, Frank SJ, Lee AK, Logothetis CJ, Kim J. Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 Mar; 117(3):469-77. PMID: 25714186; PMCID: PMC4547910 [Available on 03/01/17].
    20. Pasqualini R, Millikan RE, Christianson DR, Cardó-Vila M, Driessen WH, Giordano RJ, Hajitou A, Hoang AG, Wen S, Barnhart KF, Baze WB, Marcott VD, Hawke DH, Do KA, Navone NM, Efstathiou E, Troncoso P, Lobb RR, Logothetis CJ, Arap W. Targeting the interleukin-11 receptor ? in metastatic prostate cancer: A first-in-man study. Cancer. 2015 Jul 15; 121(14):2411-21. PMID: 25832466.
      View in: PubMed
    21. Mandelin J, Cardó-Vila M, Driessen WH, Mathew P, Navone NM, Lin SH, Logothetis CJ, Rietz AC, Dobroff AS, Proneth B, Sidman RL, Pasqualini R, Arap W. Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors. Proc Natl Acad Sci U S A. 2015 Mar 24; 112(12):3776-81. PMID: 25762070.
      View in: PubMed
    22. Mintz PJ, Rietz AC, Cardó-Vila M, Ozawa MG, Dondossola E, Do KA, Kim J, Troncoso P, Logothetis CJ, Sidman RL, Pasqualini R, Arap W. Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer. Proc Natl Acad Sci U S A. 2015 Feb 24; 112(8):2515-20. PMID: 25675522.
      View in: PubMed
    23. Morris MJ, Molina A, Small EJ, de Bono JS, Logothetis CJ, Fizazi K, de Souza P, Kantoff PW, Higano CS, Li J, Kheoh T, Larson SM, Matheny SL, Naini V, Burzykowski T, Griffin TW, Scher HI, Ryan CJ. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. J Clin Oncol. 2015 Apr 20; 33(12):1356-63. PMID: 25624432.
      View in: PubMed
    24. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb; 16(2):152-60. PMID: 25601341.
      View in: PubMed
    25. Attard G, de Bono JS, Logothetis CJ, Fizazi K, Mukherjee SD, Joshua AM, Schrijvers D, van den Eertwegh AJ, Li W, Molina A, Griffin TW, Kheoh T, Ricci DS, Zelinsky K, Rathkopf DE, Scher HI, Ryan CJ. Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. Clin Cancer Res. 2015 Apr 1; 21(7):1621-7. PMID: 25593303.
      View in: PubMed
    26. Lee YC, Gajdosik MS, Josic D, Clifton JG, Logothetis C, Yu-Lee LY, Gallick GE, Maity SN, Lin SH. Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment. Mol Cell Proteomics. 2015 Mar; 14(3):471-83. PMID: 25527621; PMCID: PMC4349970.
    27. Fizazi K, Pagliaro L, Laplanche A, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Culine S. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol. 2014 Dec; 15(13):1442-50. PMID: 25456363.
      View in: PubMed
    28. Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014 Nov 20; 32(33):3705-15. PMID: 25311217.
      View in: PubMed
    29. Bilen MA, Reyes A, Bhowmick D, Maa A, Bast R, Pisters LL, Lin SH, Logothetis CJ, Tu SM. Variant prostate carcinoma and elevated serum CA-125. Can J Urol. 2014 Oct; 21(5):7442-8. PMID: 25347368.
      View in: PubMed
    30. He Y, Gu J, Strom S, Logothetis CJ, Kim J, Wu X. The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients. Clin Cancer Res. 2014 Oct 1; 20(19):5133-9. PMID: 25274378.
      View in: PubMed
    31. Chan CH, Jo U, Kohrman A, Rezaeian AH, Chou PC, Logothetis C, Lin HK. Posttranslational regulation of Akt in human cancer. Cell Biosci. 2014; 4(1):59. PMID: 25309720.
      View in: PubMed
    32. Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M, George DJ, Higano CS, Harzstark AL, Sartor AO, Vogelzang NJ, Gordon MS, de Bono JS, Haas NB, Logothetis CJ, Elfiky A, Scheffold C, Laird AD, Schimmoller F, Basch EM, Scher HI. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol. 2014 Oct 20; 32(30):3391-9. PMID: 25225437.
      View in: PubMed
    33. Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Li Ning Tapia EM, Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci Transl Med. 2014 Sep 3; 6(252):252ra122. PMID: 25186177; PMCID: PMC4407499.
    34. Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A, Corn PG, Tannir NM, Wong FC, Fisch MJ, Logothetis CJ, Tu SM. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer. 2015 Jan 1; 121(1):69-76. PMID: 25155428.
      View in: PubMed
    35. Madsen LT, Kuban DA, Choi S, Davis JW, Kim J, Lee AK, Domain D, Levy L, Pisters LL, Pettaway CA, Ward JF, Logothetis C, Hoffman KE. Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic. J Natl Compr Canc Netw. 2014 Jul; 12(7):993-8. PMID: 24994920.
      View in: PubMed
    36. Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol. 2015 Jan; 67(1):53-60. PMID: 24882673.
      View in: PubMed
    37. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Jun; 15(7):700-12. PMID: 24831977; PMCID: PMC4418935.
    38. Logothetis CJ. Prostate cancer bone metastases: not so systemic after all. Lancet Oncol. 2014 Jun; 15(7):675-6. PMID: 24836275.
      View in: PubMed
    39. Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H, Logothetis C, Rubin MA. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res. 2014 Jun 1; 20(11):2846-50. PMID: 24727321; PMCID: PMC4040316.
    40. Gorlov IP, Yang JY, Byun J, Logothetis C, Gorlova OY, Do KA, Amos C. How to get the most from microarray data: advice from reverse genomics. BMC Genomics. 2014; 15:223. PMID: 24656147.
      View in: PubMed
    41. Gorlova O, Fedorov A, Logothetis C, Amos C, Gorlov I. Genes with a large intronic burden show greater evolutionary conservation on the protein level. BMC Evol Biol. 2014; 14(1):50. PMID: 24629165.
      View in: PubMed
    42. Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014 Nov; 66(5):815-25. PMID: 24647231.
      View in: PubMed
    43. Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res. 2014 Mar 15; 74(6):1651-60. PMID: 24473064.
      View in: PubMed
    44. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013 Dec 5; 155(6):1309-22. PMID: 24315100.
      View in: PubMed
    45. Zhao H, Logothetis CJ, Gorlov IP, Zeng J, Dai J. Modified logistic regression models using gene coexpression and clinical features to predict prostate cancer progression. Comput Math Methods Med. 2013; 2013:917502. PMID: 24367394.
      View in: PubMed
    46. Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 2013 Dec; 14(13):1307-16. PMID: 24211163.
      View in: PubMed
    47. Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, Mainwaring PN, Hao Y, Griffin T, Li S, Meyers ML, Molina A, Cleeland C. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol. 2013 Nov; 14(12):1193-9. PMID: 24075621.
      View in: PubMed
    48. Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer. 2013 Nov; 49(17):3648-57. PMID: 23973186.
      View in: PubMed
    49. Chan CH, Morrow JK, Li CF, Gao Y, Jin G, Moten A, Stagg LJ, Ladbury JE, Cai Z, Xu D, Logothetis CJ, Hung MC, Zhang S, Lin HK. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell. 2013 Aug 1; 154(3):556-68. PMID: 23911321; PMCID: PMC3845452.
    50. Logothetis CJ. Re: intratumor heterogeneity and branched evolution revealed by multiregion sequencing. Eur Urol. 2013 Jul; 64(1):170. PMID: 23746321.
      View in: PubMed
    51. Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov. 2013 Aug; 3(8):849-61. PMID: 23811619; PMCID: PMC3926428.
    52. Autio KA, Bennett AV, Jia X, Fruscione M, Beer TM, George DJ, Carducci MA, Logothetis CJ, Kane RC, Sit L, Rogak L, Morris MJ, Scher HI, Basch EM. Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure. J Oncol Pract. 2013 Sep; 9(5):223-9. PMID: 23943897; PMCID: PMC3994234.
    53. Logothetis CJ. Treatment of castrate-resistant prostate cancer. J Urol. 2013 Aug; 190(2):439-40. PMID: 23707438.
      View in: PubMed
    54. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013 Jul 1; 19(13):3621-30. PMID: 23649003; PMCID: PMC3699964.
    55. Varkaris A, Gaur S, Parikh NU, Song JH, Dayyani F, Jin JK, Logothetis CJ, Gallick GE. Ligand-independent activation of MET through IGF-1/IGF-1R signaling. Int J Cancer. 2013 Oct 1; 133(7):1536-46. PMID: 23526299; PMCID: PMC3713179.
    56. Dayyani F, Varkaris A, Araujo JC, Song JH, Chatterji T, Trudel GC, Logothetis CJ, Gallick GE. Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer. Prostate. 2013 Jun; 73(9):979-85. PMID: 23371521; PMCID: PMC4013833.
    57. Lee YC, Jin JK, Cheng CJ, Huang CF, Song JH, Huang M, Brown WS, Zhang S, Yu-Lee LY, Yeh ET, McIntyre BW, Logothetis CJ, Gallick GE, Lin SH. Targeting constitutively activated ?1 integrins inhibits prostate cancer metastasis. Mol Cancer Res. 2013 Apr; 11(4):405-17. PMID: 23339185; PMCID: PMC3631285.
    58. Dayyani F, Parikh NU, Varkaris AS, Song JH, Moorthy S, Chatterji T, Maity SN, Wolfe AR, Carboni JM, Gottardis MM, Logothetis CJ, Gallick GE. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways. PLoS One. 2012; 7(12):e51189. PMID: 23300537; PMCID: PMC3530555.
    59. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10; 368(2):138-48. PMID: 23228172.
      View in: PubMed
    60. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013 Feb 1; 31(4):412-9. PMID: 23169517; PMCID: PMC4110249.
    61. Gorlov IP, Logothetis CJ, Fang S, Gorlova OY, Amos C. Building a statistical model for predicting cancer genes. PLoS One. 2012; 7(11):e49175. PMID: 23166609; PMCID: PMC3499550.
    62. Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN, Efstathiou E, Gagnon DD, Rothman M, Hao Y, Liu CS, Kheoh TS, Haqq CM, Scher HI, de Bono JS. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012 Dec; 13(12):1210-7. PMID: 23142059.
      View in: PubMed
    63. McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, Choi SL, Nguyen QN, Hoffman KE, Pugh TJ, Frank SJ, Corn PG, Logothetis CJ, Kuban DA. PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era. Int J Radiat Oncol Biol Phys. 2013 Jan 1; 85(1):e39-46. PMID: 23102837; PMCID: PMC3840533.
    64. Som A, Tu SM, Liu J, Wang X, Qiao W, Logothetis C, Corn PG. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials. Br J Cancer. 2012 Oct 23; 107(9):1547-53. PMID: 23033003; PMCID: PMC3493771.
    65. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012 Oct; 13(10):983-92. PMID: 22995653.
      View in: PubMed
    66. Tu SM, Som A, Tu B, Logothetis CJ, Lee MH, Yeung SC. Effect of Paget's disease of bone (osteitis deformans) on the progression of prostate cancer bone metastasis. Br J Cancer. 2012 Aug 7; 107(4):646-51. PMID: 22805323.
      View in: PubMed
    67. Efstathiou E, Karlou M, Wen S, Hoang A, Pettaway CA, Pisters LL, Maity S, Troncoso P, Logothetis CJ. Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers. Prostate. 2013 Jan; 73(2):153-61. PMID: 22753310; PMCID: PMC3878994.
    68. Sharma P, Logothetis C. Prostate cancer: combination of vaccine plus ipilimumab--safety and toxicity. Nat Rev Urol. 2012 Jun; 9(6):302-3. PMID: 22565371.
      View in: PubMed
    69. Gorlov IP, Byun J, Logothetis CJ. In silico functional profiling of individual prostate cancer tumors: many genes, few functions. Cancer Genomics Proteomics. 2012 May-Jun; 9(3):109-14. PMID: 22593245; PMCID: PMC3922615.
    70. Gorlov IP, Byun J, Zhao H, Logothetis CJ, Gorlova OY. Beyond comparing means: the usefulness of analyzing interindividual variation in gene expression for identifying genes associated with cancer development. J Bioinform Comput Biol. 2012 Apr; 10(2):1241013. PMID: 22809348; PMCID: PMC3893106.
    71. Karlou M, Lu JF, Wu G, Maity S, Tzelepi V, Navone NM, Hoang A, Logothetis CJ, Efstathiou E. Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate. 2012 Nov; 72(15):1638-47. PMID: 22457212.
      View in: PubMed
    72. Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, Molina A, Chieffo N, Smith LA, Karlou M, Troncoso P, Logothetis CJ. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol. 2012 Feb 20; 30(6):637-43. PMID: 22184395; PMCID: PMC3295561.
    73. Kim J, Amos CI, Logothetis C. 5a-Reductase inhibitors for prostate-cancer prevention. N Engl J Med. 2011 Dec 15; 365(24):2340. PMID: 22168662.
      View in: PubMed
    74. Li J, Ding Z, Wang Z, Lu JF, Maity SN, Navone NM, Logothetis CJ, Mills GB, Kim J. Androgen regulation of 5?-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. PLoS One. 2011; 6(12):e28840. PMID: 22194926; PMCID: PMC3237548.
    75. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, Troncoso P, Liang S, Logothetis CJ, Maity SN, Aparicio AM. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res. 2012 Feb 1; 18(3):666-77. PMID: 22156612; PMCID: PMC3923417.
    76. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, Araujo JC, Troncoso P, Logothetis CJ, Innis JW, Smith DC, Lao CD, Kim SY, Roberts JS, Gruber SB, Pienta KJ, Talpaz M, Chinnaiyan AM. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011 Nov 30; 3(111):111ra121. PMID: 22133722.
      View in: PubMed
    77. Logothetis CJ. Treatment of prostate cancer metastases: more than semantics. Lancet. 2012 Jan 7; 379(9810):4-6. PMID: 22093188.
      View in: PubMed
    78. Staquicini FI, Cardó-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O'Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A. 2011 Nov 15; 108(46):18637-42. PMID: 22049339; PMCID: PMC3219136.
    79. Aparicio A, Logothetis CJ, Maity SN. Understanding the lethal variant of prostate cancer: power of examining extremes. Cancer Discov. 2011 Nov; 1(6):466-8. PMID: 22586648.
      View in: PubMed
    80. Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs. 2011 Dec; 20(12):1677-84. PMID: 22035268.
      View in: PubMed
    81. Dayyani F, Gallick GE, Logothetis CJ, Corn PG. Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst. 2011 Nov 16; 103(22):1665-75. PMID: 21917607; PMCID: PMC4176261.
    82. Zurita AJ, George DJ, Shore ND, Liu G, Wilding G, Hutson TE, Kozloff M, Mathew P, Harmon CS, Wang SL, Chen I, Maneval EC, Logothetis CJ. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Ann Oncol. 2012 Mar; 23(3):688-94. PMID: 21821830.
      View in: PubMed
    83. Logothetis CJ, Efstathiou E, Manuguid F, Kirkpatrick P. Abiraterone acetate. Nat Rev Drug Discov. 2011 Aug; 10(8):573-4. PMID: 21804589.
      View in: PubMed
    84. Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer. 2012 Jan 1; 118(1):63-71. PMID: 21976132; PMCID: PMC3898168.
    85. Ye X, Lee YC, Choueiri M, Chu K, Huang CF, Tsai WW, Kobayashi R, Logothetis CJ, Yu-Lee LY, Lin SH. Aberrant expression of katanin p60 in prostate cancer bone metastasis. Prostate. 2012 Feb; 72(3):291-300. PMID: 21681775; PMCID: PMC3179562.
    86. Tzelepi V, Karlou M, Wen S, Hoang A, Logothetis C, Troncoso P, Efstathiou E. Expression of hedgehog pathway components in prostate carcinoma microenvironment: shifting the balance towards autocrine signalling. Histopathology. 2011 Jun; 58(7):1037-47. PMID: 21707705.
      View in: PubMed
    87. Logothetis CJ. When 'dueling technologies' are mistaken for progress. BJU Int. 2011 Jun; 107(11):1699-700. PMID: 21592278; PMCID: PMC3922611.
    88. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011 Jul 15; 17(14):4854-61. PMID: 21632851.
      View in: PubMed
    89. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26; 364(21):1995-2005. PMID: 21612468; PMCID: PMC3471149.
    90. Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway CA, Pisters LL, Hoang A, Logothetis CJ, Pagliaro LC. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol. 2011 Jun 20; 29(18):2574-81. PMID: 21606419; PMCID: PMC3138635.
    91. Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, Xu L, Herynk MH, McKee KS, Tran HT, Logothetis CJ, Tannir NM, Heymach JV. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2012 Jan; 23(1):46-52. PMID: 21464158.
      View in: PubMed
    92. Bracarda S, Logothetis C, Sternberg CN, Oudard S. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. BJU Int. 2011 Apr; 107 Suppl 2:13-20. PMID: 21382150.
      View in: PubMed
    93. Fitzpatrick JM, Bellmunt J, Dreicer R, Fleshner NE, Logothetis CJ, Moul JW, Tombal B, Zlotta A. Maximizing outcomes in genitourinary cancers across the treatment continuum. BJU Int. 2011 Apr; 107 Suppl 2:1-12. PMID: 21382149.
      View in: PubMed
    94. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate. 2011 Jun 1; 71(8):846-56. PMID: 21456067; PMCID: PMC3883511.
    95. Gorlov IP, Sircar K, Zhao H, Maity SN, Navone NM, Gorlova OY, Troncoso P, Pettaway CA, Byun JY, Logothetis CJ. Prioritizing genes associated with prostate cancer development. BMC Cancer. 2010; 10:599. PMID: 21044312; PMCID: PMC2988752.
    96. Prantl L, Muehlberg F, Navone NM, Song YH, Vykoukal J, Logothetis CJ, Alt EU. Adipose tissue-derived stem cells promote prostate tumor growth. Prostate. 2010 Nov 1; 70(15):1709-15. PMID: 20564322.
      View in: PubMed
    97. Huang CF, Lira C, Chu K, Bilen MA, Lee YC, Ye X, Kim SM, Ortiz A, Wu FL, Logothetis CJ, Yu-Lee LY, Lin SH. Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Res. 2010 Jun 1; 70(11):4580-9. PMID: 20484040; PMCID: PMC2923552.
    98. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010 May 15; 16(10):2861-71. PMID: 20460488.
      View in: PubMed
    99. Tu SM, Lin SH, Podoloff DA, Logothetis CJ. Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer. Clin Adv Hematol Oncol. 2010 May; 8(5):341-51. PMID: 20551894.
      View in: PubMed
    100. Zhao H, Logothetis CJ, Gorlov IP. Usefulness of the top-scoring pairs of genes for prediction of prostate cancer progression. Prostate Cancer Prostatic Dis. 2010 Sep; 13(3):252-9. PMID: 20386565.
      View in: PubMed
    101. Logothetis CJ, Siefker-Radtke A. Words of wisdom. Re: final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. Eur Urol. 2010 Apr; 57(4):728-9. PMID: 20965043.
      View in: PubMed
    102. Araujo J, Logothetis C. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev. 2010 Oct; 36(6):492-500. PMID: 20226597.
      View in: PubMed
    103. Efstathiou E, Logothetis CJ. A new therapy paradigm for prostate cancer founded on clinical observations. Clin Cancer Res. 2010 Feb 15; 16(4):1100-7. PMID: 20145177.
      View in: PubMed
    104. Byun J, Logothetis CJ, Gorlov IP. Housekeeping genes in prostate tumorigenesis. Int J Cancer. 2009 Dec 1; 125(11):2603-8. PMID: 19551858; PMCID: PMC4531049.
    105. Araujo JC, Poblenz A, Corn P, Parikh NU, Starbuck MW, Thompson JT, Lee F, Logothetis CJ, Darnay BG. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation. Cancer Biol Ther. 2009 Nov; 8(22):2153-9. PMID: 19855158; PMCID: PMC4073296.
    106. Efstathiou E, Abrahams NA, Tibbs RF, Wang X, Pettaway CA, Pisters LL, Mathew PF, Do KA, Logothetis CJ, Troncoso P. Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification. Eur Urol. 2010 Jun; 57(6):1030-8. PMID: 19853370.
      View in: PubMed
    107. Efstathiou E, Kim J, Logothetis CJ. Informative clinical investigation: a demanding taskmaster. J Clin Oncol. 2009 Oct 20; 27(30):4937-8. PMID: 19720892.
      View in: PubMed
    108. Gorlov IP, Byun J, Gorlova OY, Aparicio AM, Efstathiou E, Logothetis CJ. Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. BMC Med Genomics. 2009; 2:48. PMID: 19653896; PMCID: PMC2731785.
    109. Gorlov IP, Gallick GE, Gorlova OY, Amos C, Logothetis CJ. GWAS meets microarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate cancer as an example. PLoS One. 2009; 4(8):e6511. PMID: 19652704.
      View in: PubMed
    110. Thompson TC, Tahir SA, Li L, Watanabe M, Naruishi K, Yang G, Kadmon D, Logothetis CJ, Troncoso P, Ren C, Goltsov A, Park S. The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis. 2010 Mar; 13(1):6-11. PMID: 19581923; PMCID: PMC2887695.
    111. Tu SM, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol. 2009 Jul 10; 27(20):3319-24. PMID: 19414670.
      View in: PubMed
    112. Efstathiou E, Logothetis CJ. Prostate cancer: thalidomide for prostate cancer: is there progress? Nat Rev Urol. 2009 May; 6(5):248-50. PMID: 19424170.
      View in: PubMed
    113. Daliani DD, Tannir NM, Papandreou CN, Wang X, Swisher S, Wood CG, Swanson DA, Logothetis CJ, Jonasch E. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int. 2009 Aug; 104(4):456-60. PMID: 19338544.
      View in: PubMed
    114. Gnjatic S, Altorki NK, Tang DN, Tu SM, Kundra V, Ritter G, Old LJ, Logothetis CJ, Sharma P. NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res. 2009 Mar 15; 15(6):2130-9. PMID: 19276258.
      View in: PubMed
    115. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4; 101(5):306-20. PMID: 19244175.
      View in: PubMed
    116. Pataer A, Swisher SG, Roth JA, Logothetis CJ, Corn PG. Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity. Cancer Biol Ther. 2009 Feb; 8(3):245-52. PMID: 19106640; PMCID: PMC2854203.
    117. Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, Sun J, Jungbluth AA, Troncoso P, Logothetis C, Sharma P. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A. 2009 Feb 24; 106(8):2729-34. PMID: 19202079; PMCID: PMC2650334.
    118. Araujo J, Logothetis C. Targeting Src signaling in metastatic bone disease. Int J Cancer. 2009 Jan 1; 124(1):1-6. PMID: 18942061.
      View in: PubMed
    119. Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI. Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer. 2009 Jan; 7(1):51-7. PMID: 19213669.
      View in: PubMed
    120. Millikan RE, Wen S, Pagliaro LC, Brown MA, Moomey B, Do KA, Logothetis CJ. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol. 2008 Dec 20; 26(36):5936-42. PMID: 19029421; PMCID: PMC3864402.
    121. Mathew P, Thall PF, Wen S, Bucana C, Jones D, Horne E, Oh WK, Morris MJ, Lee YC, Logothetis CJ, Lin SH, Fidler IJ. Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer. Br J Cancer. 2008 Nov 4; 99(9):1426-32. PMID: 18841158; PMCID: PMC2579696.
    122. Tsao CC, Teh BT, Jonasch E, Shreiber-Agus N, Efstathiou E, Hoang A, Czerniak B, Logothetis C, Corn PG. Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis. Cancer Biol Ther. 2008 Oct; 7(10):1619-27. PMID: 19018165.
      View in: PubMed
    123. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C, Sharma P. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A. 2008 Sep 30; 105(39):14987-92. PMID: 18818309; PMCID: PMC2567480.
    124. Chu K, Cheng CJ, Ye X, Lee YC, Zurita AJ, Chen DT, Yu-Lee LY, Zhang S, Yeh ET, Hu MC, Logothetis CJ, Lin SH. Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res. 2008 Aug; 6(8):1259-67. PMID: 18708358; PMCID: PMC2643879.
    125. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest. 2008 Aug; 118(8):2697-710. PMID: 18618013; PMCID: PMC2447924.
    126. Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res. 2008 Jun 15; 14(12):3729-36. PMID: 18559590; PMCID: PMC2562877.
    127. Logothetis CJ, Millikan R. Chemotherapy for advanced prostate cancer: 25 years later. J Clin Oncol. 2008 May 20; 26(15):2423-4. PMID: 18487561.
      View in: PubMed
    128. Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene. 2008 Sep 4; 27(39):5195-203. PMID: 18490922; PMCID: PMC2562662.
    129. Logothetis CJ, Schellhammer PF. High-grade prostate cancer and the prostate cancer prevention trial. Cancer Prev Res (Phila). 2008 Aug; 1(3):151-2. PMID: 19138948.
      View in: PubMed
    130. Logothetis CJ, Navone NM, Lin SH. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin Cancer Res. 2008 Mar 15; 14(6):1599-602. PMID: 18347159.
      View in: PubMed
    131. McDonnell TJ, Chari NS, Cho-Vega JH, Troncoso P, Wang X, Bueso-Ramos CE, Coombes K, Brisbay S, Lopez R, Prendergast G, Logothetis C, Do KA. Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer. BMC Med Genomics. 2008; 1:1. PMID: 18237448.
      View in: PubMed
    132. Logothetis CJ. Strategy for the application of therapy in prostate cancer. Adv Exp Med Biol. 2008; 617:193-9. PMID: 18497043.
      View in: PubMed
    133. Thall PF, Wooten LH, Logothetis CJ, Millikan RE, Tannir NM. Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med. 2007 Nov 20; 26(26):4687-702. PMID: 17427204.
      View in: PubMed
    134. Mao S, Daliani DD, Wang X, Thall PF, Do KA, Perez CA, Brown MA, Bouchillon K, Carter CM, Logothetis CJ, Kim J. Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies. Prostate. 2007 Nov 1; 67(15):1677-85. PMID: 17879948.
      View in: PubMed
    135. Thall PF, Logothetis C, Pagliaro LC, Wen S, Brown MA, Williams D, Millikan RE. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. J Natl Cancer Inst. 2007 Nov 7; 99(21):1613-22. PMID: 17971530.
      View in: PubMed
    136. Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, Logothetis CJ, Pignon JP, Michiels S. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol. 2007 Nov; 8(11):994-1000. PMID: 17942366.
      View in: PubMed
    137. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res. 2007 Oct 1; 13(19):5816-24. PMID: 17908974.
      View in: PubMed
    138. van Adelsberg J, Gann P, Ko AT, Damber JE, Logothetis C, Marberger M, Schmitz-Drager BJ, Tubaro A, Harms CJ, Roehrborn C. The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. Curr Med Res Opin. 2007 Sep; 23(9):2063-70. PMID: 17651539.
      View in: PubMed
    139. Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, Mathew P, Lopez A, Logothetis CJ, Lin SH, Navone NM. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene. 2008 Jan 24; 27(5):596-603. PMID: 17700537.
      View in: PubMed
    140. Mohler J, Babaian RJ, Bahnson RR, Boston B, D'Amico A, Eastham JA, Hauke RJ, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Logothetis C, MacVicar G, Pollack A, Pow-Sang JM, Roach M, Sandler H, Shrieve D, Srinivas S, Twardowski P, Urban DA, Walsh PC. Prostate cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Aug; 5(7):650-83. PMID: 17692170.
      View in: PubMed
    141. Chen N, Ye XC, Chu K, Navone NM, Sage EH, Yu-Lee LY, Logothetis CJ, Lin SH. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res. 2007 Jul 15; 67(14):6544-8. PMID: 17638862; PMCID: PMC2000837.
    142. Liakou CI, Narayanan S, Ng Tang D, Logothetis CJ, Sharma P. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun. 2007; 7:10. PMID: 17591743.
      View in: PubMed
    143. Efstathiou E, Troncoso P, Wen S, Do KA, Pettaway CA, Pisters LL, McDonnell TJ, Logothetis CJ. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1224-31. PMID: 17317833.
      View in: PubMed
    144. Wang J, Do KA, Wen S, Tsavachidis S, McDonnell TJ, Logothetis CJ, Coombes KR. Merging microarray data, robust feature selection, and predicting prognosis in prostate cancer. Cancer Inform. 2006; 2:87-97. PMID: 19458761.
      View in: PubMed
    145. Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar KS, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J. Testicular cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Nov; 4(10):1038-58. PMID: 17112452.
      View in: PubMed
    146. Efstathiou E, Logothetis CJ. Review of late complications of treatment and late relapse in testicular cancer. J Natl Compr Canc Netw. 2006 Nov; 4(10):1059-70. PMID: 17112453.
      View in: PubMed
    147. Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer. 2006 Nov 1; 107(9):2254-61. PMID: 17029276.
      View in: PubMed
    148. Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar K, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J. Kidney cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Nov; 4(10):1072-81. PMID: 17112454.
      View in: PubMed
    149. Mathew P, Logothetis CJ, Dieringer PY, Chen I, Pagliaro LC, Bekele BN, Zhou X, Daliani DD. Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer. Clin Genitourin Cancer. 2006 Sep; 5(2):144-9. PMID: 17026803.
      View in: PubMed
    150. Spurgers KB, Gold DL, Coombes KR, Bohnenstiehl NL, Mullins B, Meyn RE, Logothetis CJ, McDonnell TJ. Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J Biol Chem. 2006 Sep 1; 281(35):25134-42. PMID: 16798743.
      View in: PubMed
    151. Kim SJ, Uehara H, Yazici S, Busby JE, Nakamura T, He J, Maya M, Logothetis C, Mathew P, Wang X, Do KA, Fan D, Fidler IJ. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst. 2006 Jun 7; 98(11):783-93. PMID: 16757703.
      View in: PubMed
    152. Subbarayan V, Krieg P, Hsi LC, Kim J, Yang P, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. 15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor gamma. Oncogene. 2006 Sep 28; 25(44):6015-25. PMID: 16682954.
      View in: PubMed
    153. Leibovici D, Kamat AM, Pettaway CA, Pagliaro L, Rosser CJ, Logothetis C, Pisters LL. Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol. 2005 Dec; 174(6):2186-90. PMID: 16280761.
      View in: PubMed
    154. Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol. 2005 Nov 10; 23(32):8232-41. PMID: 16278478.
      View in: PubMed
    155. Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol. 2005 Nov 1; 23(31):7904-10. PMID: 16258090.
      View in: PubMed
    156. Strom SS, Wang X, Pettaway CA, Logothetis CJ, Yamamura Y, Do KA, Babaian RJ, Troncoso P. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res. 2005 Oct 1; 11(19 Pt 1):6889-94. PMID: 16203779.
      View in: PubMed
    157. Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, Mendoza G, Subbarayan V, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res. 2005 Jul 15; 65(14):6189-98. PMID: 16024620.
      View in: PubMed
    158. Kim J, Sun P, Lam YW, Troncoso P, Sabichi AL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lippman SM, McDonnell TJ, Lieberman R, Logothetis C, Ho SM. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2005 Jul; 14(7):1697-702. PMID: 16030104.
      View in: PubMed
    159. Cho-Vega JH, Troncoso P, Do KA, Rago C, Wang X, Tsavachidis S, Medeiros LJ, Spurgers K, Logothetis C, McDonnell TJ. Combined laser capture microdissection and serial analysis of gene expression from human tissue samples. Mod Pathol. 2005 Apr; 18(4):577-84. PMID: 15529182.
      View in: PubMed
    160. Subbarayan V, Xu XC, Kim J, Yang P, Hoque A, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia. 2005 Mar; 7(3):280-93. PMID: 15799828; PMCID: PMC1501140.
    161. Motzer RJ, Bahnson RR, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Redman BG, Richey S, Robertson CN, Samlowski WE, Sheinfeld J, Urban DA. Testicular cancer. Clinical practice guidelines. J Natl Compr Canc Netw. 2005 Jan; 3(1):52-76. PMID: 19813323.
      View in: PubMed
    162. Motzer RJ, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pili R, Pohar KS, Redman BG, Richey S, Robertson CN, Samlowski WE, Sheinfeld J, Urban DA. Kidney cancer. Clinical practice guidelines. J Natl Compr Canc Netw. 2005 Jan; 3(1):84-93. PMID: 19813325.
      View in: PubMed
    163. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer. 2005 Jan; 5(1):21-8. PMID: 15630412.
      View in: PubMed
    164. Wyatt RB, Sánchez-Ortiz RF, Wood CG, Ramirez E, Logothetis C, Pettaway CA. Prognostic factors for survival among Caucasian, African-American and Hispanic men with androgen-independent prostate cancer. J Natl Med Assoc. 2004 Dec; 96(12):1587-93. PMID: 15622688; PMCID: PMC2568655.
    165. Subbarayan V, Sabichi AL, Kim J, Llansa N, Logothetis CJ, Lippman SM, Menter DG. Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol Biomarkers Prev. 2004 Nov; 13(11 Pt 1):1710-6. PMID: 15533897.
      View in: PubMed
    166. Assikis VJ, Do KA, Wen S, Wang X, Cho-Vega JH, Brisbay S, Lopez R, Logothetis CJ, Troncoso P, Papandreou CN, McDonnell TJ. Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clin Cancer Res. 2004 Oct 15; 10(20):6770-8. PMID: 15501953.
      View in: PubMed
    167. Fizazi K, Sikes CR, Kim J, Yang J, Martinez LA, Olive MC, Logothetis CJ, Navone NM. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res. 2004 Sep-Oct; 24(5A):2897-903. PMID: 15517894.
      View in: PubMed
    168. Strom SS, Gu Y, Zhang H, Troncoso P, Babaian RJ, Pettaway CA, Shete S, Spitz MR, Logothetis CJ. Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Prostate. 2004 Sep 1; 60(4):343-51. PMID: 15264247.
      View in: PubMed
    169. Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P, Kim SJ, Fidler IJ, Logothetis C. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol. 2004 Aug 15; 22(16):3323-9. PMID: 15310776.
      View in: PubMed
    170. Fizazi K, Culine S, Kramar A, Amato RJ, Bouzy J, Chen I, Droz JP, Logothetis CJ. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol. 2004 Oct 1; 22(19):3868-76. PMID: 15302906.
      View in: PubMed
    171. Papandreou CN, Logothetis CJ. Bortezomib as a potential treatment for prostate cancer. Cancer Res. 2004 Aug 1; 64(15):5036-43. PMID: 15289299.
      View in: PubMed
    172. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004 Jun 1; 22(11):2108-21. PMID: 15169797.
      View in: PubMed
    173. Pisters LL, Pettaway CA, Troncoso P, McDonnell TJ, Stephens LC, Wood CG, Do KA, Brisbay SM, Wang X, Hossan EA, Evans RB, Soto C, Jacobson MG, Parker K, Merritt JA, Steiner MS, Logothetis CJ. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res. 2004 Apr 15; 10(8):2587-93. PMID: 15102659.
      View in: PubMed
    174. Mathew P, Fidler IJ, Logothetis CJ. Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Semin Oncol. 2004 Apr; 31(2 Suppl 6):24-9. PMID: 15176001.
      View in: PubMed
    175. Spurgers KB, Coombes KR, Meyn RE, Gold DL, Logothetis CJ, Johnson TJ, McDonnell TJ. A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells. Oncogene. 2004 Mar 4; 23(9):1712-23. PMID: 14647426.
      View in: PubMed
    176. Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem. 2004 Apr 30; 279(18):19191-200. PMID: 14985354.
      View in: PubMed
    177. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004 Feb 1; 22(3):537-56. PMID: 14752077.
      View in: PubMed
    178. Zurita AJ, Troncoso P, Cardó-Vila M, Logothetis CJ, Pasqualini R, Arap W. Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res. 2004 Jan 15; 64(2):435-9. PMID: 14744752.
      View in: PubMed
    179. Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, Millikan RE. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol. 2004 Jan; 171(1):145-8. PMID: 14665863.
      View in: PubMed
    180. Logothetis CJ. The case for a biologically based classification of prostate cancer. Semin Oncol. 2003 Oct; 30(5):562-6. PMID: 14571406.
      View in: PubMed
    181. Logothetis CJ. Foundation for the integration of biologically based therapy in the management of prostate cancer. Prostate. 2003 Sep 15; 57(1):32-8. PMID: 12886521.
      View in: PubMed
    182. Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther. 2003 Sep; 2(9):835-43. PMID: 14555702.
      View in: PubMed
    183. Tu SM, Millikan RE, Pagliaro LC, Daliani D, Papandreou CN, Kim J, Chen DT, Williams DL, Logothetis CJ. Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP). Urol Oncol. 2003 Sep-Oct; 21(5):342-8. PMID: 14670540.
      View in: PubMed
    184. Tu SM, Lin SH, Logothetis C. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2003 Aug 6; 95(15):1174-5; author reply 1175. PMID: 12902452.
      View in: PubMed
    185. Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res. 2003 Jul; 9(7):2587-97. PMID: 12855635.
      View in: PubMed
    186. Pagliaro LC, Delpassand ES, Williams D, Millikan RE, Tu SM, Logothetis CJ. A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer. 2003 Jun 15; 97(12):2988-94. PMID: 12784333.
      View in: PubMed
    187. Bruckheimer EM, Spurgers K, Weigel NL, Logothetis C, McDonnell TJ. Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. J Urol. 2003 Apr; 169(4):1553-7. PMID: 12629413.
      View in: PubMed
    188. Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, Killion JJ, Logothetis C, Mathew P, Fidler IJ. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst. 2003 Mar 19; 95(6):458-70. PMID: 12644539.
      View in: PubMed
    189. Millikan R, Thall PF, Lee SJ, Jones D, Cannon MW, Kuebler JP, Wade J, Logothetis CJ. Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. J Clin Oncol. 2003 Mar 1; 21(5):878-83. PMID: 12610188.
      View in: PubMed
    190. Logothetis C, Tu SM, Navone N. Targeting prostate cancer bone metastases. Cancer. 2003 Feb 1; 97(3 Suppl):785-8. PMID: 12548576.
      View in: PubMed
    191. Daliani DD, Assikis V, Tu SM, Papandreou CN, Pagliaro LC, Holtkamp T, Wang X, Thall PF, Logothetis CJ. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer. 2003 Feb 1; 97(3):561-7. PMID: 12548597.
      View in: PubMed
    192. Kim J, Millikan RE, Smith TL, Tu SM, Pagliaro LC, Logothetis CJ. Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study. Urol Oncol. 2003 Jan-Feb; 21(1):21-6. PMID: 12684123.
      View in: PubMed
    193. Pentz RD, Flamm AL, Pasqualini R, Logothetis CJ, Arap W. Revisiting ethical guidelines for research with terminal wean and brain-dead participants. Hastings Cent Rep. 2003 Jan-Feb; 33(1):20-6. PMID: 12613384.
      View in: PubMed
    194. Mintz PJ, Kim J, Do KA, Wang X, Zinner RG, Cristofanilli M, Arap MA, Hong WK, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol. 2003 Jan; 21(1):57-63. PMID: 12496764.
      View in: PubMed
    195. Logothetis CJ. Challenge of locally persistent prostate cancer: an unresolved clinical dilemma. J Clin Oncol. 2002 Aug 1; 20(15):3187. PMID: 12149287.
      View in: PubMed
    196. Martinez LA, Yang J, Vazquez ES, Rodriguez-Vargas Mdel C, Olive M, Hsieh JT, Logothetis CJ, Navone NM. p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis. 2002 Aug; 23(8):1289-96. PMID: 12151346.
      View in: PubMed
    197. Pu YS, Do KA, Luo W, Logothetis CJ, Lin SH. Enhanced suppression of prostate tumor growth by combining C-CAM1 gene therapy and angiogenesis inhibitor TNP-470. Anticancer Drugs. 2002 Aug; 13(7):743-9. PMID: 12187331.
      View in: PubMed
    198. Tu SM, Lin SH, Logothetis CJ. Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol. 2002 Aug; 3(8):508-13. PMID: 12147437.
      View in: PubMed
    199. Volpert O, Luo W, Liu TJ, Estrera VT, Logothetis C, Lin SH. Inhibition of prostate tumor angiogenesis by the tumor suppressor CEACAM1. J Biol Chem. 2002 Sep 20; 277(38):35696-702. PMID: 12122002.
      View in: PubMed
    200. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, Troncoso P, Logothetis CJ. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002 Jul 15; 20(14):3072-80. PMID: 12118020.
      View in: PubMed
    201. Pagliaro LC, Millikan RE, Tu SM, Williams D, Daliani D, Papandreou CN, Logothetis CJ. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol. 2002 Jul 1; 20(13):2965-70. PMID: 12089226.
      View in: PubMed
    202. Logothetis CJ. Docetaxel in the integrated management of prostate cancer. Current applications and future promise. Oncology (Williston Park). 2002 Jun; 16(6 Suppl 6):63-72. PMID: 12108899.
      View in: PubMed
    203. Logothetis C, Millikan R. Docetaxel in the management of advanced or metastatic urothelial tract cancer. Oncology (Williston Park). 2002 Jun; 16(6 Suppl 6):107-11. PMID: 12108893.
      View in: PubMed
    204. Fizazi K, Prow DM, Do KA, Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu SM, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer. 2002 May 20; 86(10):1555-60. PMID: 12085204.
      View in: PubMed
    205. Tu SM, Reyes A, Maa A, Bhowmick D, Pisters LL, Pettaway CA, Lin SH, Troncoso P, Logothetis CJ. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer. 2002 May 15; 94(10):2610-7. PMID: 12173328.
      View in: PubMed
    206. Fizazi K, Martinez LA, Sikes CR, Johnston DA, Stephens LC, McDonnell TJ, Logothetis CJ, Trapman J, Pisters LL, Ordoñez NG, Troncoso P, Navone NM. The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res. 2002 Mar; 8(3):775-81. PMID: 11895908.
      View in: PubMed
    207. Siefker-Radtke AO, Millikan RE, Tu SM, Moore DF, Smith TL, Williams D, Logothetis CJ. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol. 2002 Mar 1; 20(5):1361-7. PMID: 11870180.
      View in: PubMed
    208. Plonowski A, Schally AV, Nagy A, Groot K, Krupa M, Navone NM, Logothetis C. Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Cancer Lett. 2002 Feb 8; 176(1):57-63. PMID: 11790454.
      View in: PubMed
    209. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardó-Vila M, Giordano RJ, Mintz PJ, Ardelt PU, Yao VJ, Vidal CI, Chen L, Flamm A, Valtanen H, Weavind LM, Hicks ME, Pollock RE, Botz GH, Bucana CD, Koivunen E, Cahill D, Troncoso P, Baggerly KA, Pentz RD, Do KA, Logothetis CJ, Pasqualini R. Steps toward mapping the human vasculature by phage display. Nat Med. 2002 Feb; 8(2):121-7. PMID: 11821895.
      View in: PubMed
    210. Fizazi K, Chen I, Logothetis CJ. Germ-cell tumor survivors: the price for cure. Ann Oncol. 2002 Feb; 13(2):187-9. PMID: 11885993.
      View in: PubMed
    211. Fizazi K, Do KA, Wang X, Finn L, Logothetis CJ, Amato RJ. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial. Ann Oncol. 2002 Jan; 13(1):125-34. PMID: 11863094.
      View in: PubMed
    212. Coombes KR, Zhang L, Bueso-Ramos C, Brisbay S, Logothetis C, Roth J, Keating MJ, McDonnell TJ. TAD: a web interface and database for tissue microarrays. Appl Bioinformatics. 2002; 1(3):155-8. PMID: 15130842.
      View in: PubMed
    213. Millikan R, Dinney C, Swanson D, Sweeney P, Ro JY, Smith TL, Williams D, Logothetis C. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol. 2001 Oct 15; 19(20):4005-13. PMID: 11600601.
      View in: PubMed
    214. Newman RA, Yang J, Raymond M, Finlay V, Cabral F, Vourloumis D, Stephens LC, Troncoso P, Wu X, Logothetis CJ, Nicolaou KC, Navone NM. Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts. Cancer Chemother Pharmacol. 2001 Oct; 48(4):319-26. PMID: 11710633.
      View in: PubMed
    215. Merritt JA, Roth JA, Logothetis CJ. Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies. Semin Oncol. 2001 Oct; 28(5 Suppl 16):105-14. PMID: 11706402.
      View in: PubMed
    216. Fizazi K, Amato RJ, Beuzeboc P, Petit N, Bouhour D, Thiss A, Rebischung C, Chevreau C, Logothetis CJ, Droz JP. Germ cell tumors in patients infected by the human immunodeficiency virus. Cancer. 2001 Sep 15; 92(6):1460-7. PMID: 11745223.
      View in: PubMed
    217. Honda T, Gjertsen BT, Spurgers KB, Briones F, Lee SJ, Hobbs ML, Meyn RE, Roth JA, Logothetis C, McDonnell TJ. Restoration of bax in prostate cancer suppresses tumor growth and augments therapeutic cell death induction. Anticancer Res. 2001 Sep-Oct; 21(5):3141-6. PMID: 11848465.
      View in: PubMed
    218. Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Jamal N, Hu M, Olive M, Martinez LA, Wood CG, Logothetis CJ, Karsenty G, Navone NM. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res. 2001 Jul 15; 61(14):5652-9. PMID: 11454720.
      View in: PubMed
    219. Millikan RE, Plunkett WK, Smith TL, Williams DL, Logothetis CJ. Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin. Cancer. 2001 Jul 1; 92(1):194-9. PMID: 11443627.
      View in: PubMed
    220. Logothetis CJ, Wu KK, Finn LD, Daliani D, Figg W, Ghaddar H, Gutterman JU. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res. 2001 May; 7(5):1198-203. PMID: 11350884.
      View in: PubMed
    221. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001 Feb 3; 357(9253):336-41. PMID: 11210994.
      View in: PubMed
    222. Schumacher G, Bruckheimer EM, Beham AW, Honda T, Brisbay S, Roth JA, Logothetis C, McDonnell TJ. Molecular determinants of cell death induction following adenovirus-mediated gene transfer of wild-type p53 in prostate cancer cells. Int J Cancer. 2001 Jan 15; 91(2):159-66. PMID: 11146439.
      View in: PubMed
    223. Bahnson RR, Hanks GE, Huben RP, Kantoff P, Kozlowski JM, Kuettel M, Lange PH, Logothetis C, Pow-Sang JM, Roach M, Sandler H, Scardino PT, Taylor RJ, Urban DA, Walsh PC, Wilson TG. NCCN Practice Guidelines for Prostate Cancer. Oncology (Williston Park). 2000 Nov; 14(11A):111-9. PMID: 11195405.
      View in: PubMed
    224. Pagliaro L, Daliani D, Amato R, Tu SM, Jones D, Smith T, Logothetis C, Millikan R. A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer. 2000 Aug 1; 89(3):615-8. PMID: 10931461.
      View in: PubMed
    225. Ozen M, Hopwood VL, Balbay MD, Johnston DA, Babaian RJ, Logothetis CJ, von Eschenbach AC, Pathak S. Correlation of non-random chromosomal aberrations in lymphocytes of prostate cancer patients with specific clinical parameters. Int J Oncol. 2000 Jul; 17(1):113-7. PMID: 10853027.
      View in: PubMed
    226. Pettaway CA, Pisters LL, Troncoso P, Slaton J, Finn L, Kamoi K, Logothetis CJ. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol. 2000 Mar; 18(5):1050-7. PMID: 10694556.
      View in: PubMed
    227. Navone NM, Rodriquez-Vargas MC, Benedict WF, Troncoso P, McDonnell TJ, Zhou JH, Luthra R, Logothetis CJ. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. Clin Cancer Res. 2000 Mar; 6(3):1190-7. PMID: 10741751.
      View in: PubMed
    228. Lecrone V, Li W, Devoll RE, Logothetis C, Farach-Carson MC. Calcium signals in prostate cancer cells: specific activation by bone-matrix proteins. Cell Calcium. 2000 Jan; 27(1):35-42. PMID: 10726209.
      View in: PubMed
    229. Amato RJ, Millikan R, Daliani D, Wood L, Logothetis C, Pollack A. Cyclophosphamide and carboplatin and selective consolidation in advanced seminoma. Clin Cancer Res. 2000 Jan; 6(1):72-7. PMID: 10656434.
      View in: PubMed
    230. McCutcheon IE, Eng DY, Logothetis CJ. Brain metastasis from prostate carcinoma: antemortem recognition and outcome after treatment. Cancer. 1999 Dec 1; 86(11):2301-11. PMID: 10590371.
      View in: PubMed
    231. Park DS, Prow DM, Amato RJ, Logothetis CJ. Management consideration in nonpulmonary visceral metastatic seminoma of testis. J Korean Med Sci. 1999 Aug; 14(4):431-7. PMID: 10485624; PMCID: PMC3054405.
    232. Logothetis CJ. Introduction: a therapeutically relevant framework for the classification of human prostate cancer. Semin Oncol. 1999 Aug; 26(4):369-74. PMID: 10482179.
      View in: PubMed
    233. Luo W, Tapolsky M, Earley K, Wood CG, Wilson DR, Logothetis CJ, Lin SH. Tumor-suppressive activity of CD66a in prostate cancer. Cancer Gene Ther. 1999 Jul-Aug; 6(4):313-21. PMID: 10419049.
      View in: PubMed
    234. Kim J, Logothetis CJ. Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma. Urol Clin North Am. 1999 May; 26(2):281-90. PMID: 10361551.
      View in: PubMed
    235. Park DS, Prow DM, Amato RJ, Ro JY, Logothetis CJ. Clinical characteristics of metachronous bilateral testicular tumors in the chemotherapeutic era. Yonsei Med J. 1999 Apr; 40(2):137-43. PMID: 10333717.
      View in: PubMed
    236. Horti J, Dixon SC, Logothetis CJ, Guo Y, Reed E, Figg WD. Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor. Br J Cancer. 1999 Mar; 79(9-10):1588-93. PMID: 10188911; PMCID: PMC2362736.
    237. Czerniak B, Chaturvedi V, Li L, Hodges S, Johnston D, Roy JY, Luthra R, Logothetis C, Von Eschenbach AC, Grossman HB, Benedict WF, Batsakis JG. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene. 1999 Feb 4; 18(5):1185-96. PMID: 10022124.
      View in: PubMed
    238. Ozen M, Hopwood VL, Johnston DA, Babaian RJ, Logothetis CJ, von Eschenbach AC, Pathak S. Aneuploidy index in blood: a potential marker for early onset, androgen response, and metastasis in human prostate cancer. Urology. 1999 Feb; 53(2):381-5. PMID: 9933059.
      View in: PubMed
    239. Lin SH, Pu YS, Luo W, Wang Y, Logothetis CJ. Schedule-dependence of C-CAM1 adenovirus gene therapy in a prostate cancer model. Anticancer Res. 1999 Jan-Feb; 19(1A):337-40. PMID: 10226564.
      View in: PubMed
    240. Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, von Eschenbach AC, Logothetis CJ. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol. 1999 Jan; 161(1):304-8. PMID: 10037428.
      View in: PubMed
    241. Herrmann JL, Briones F, Brisbay S, Logothetis CJ, McDonnell TJ. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene. 1998 Dec 3; 17(22):2889-99. PMID: 9879995.
      View in: PubMed
    242. Ozen M, Navone NM, Multani AS, Troncoso P, Logothetis CJ, Chung LW, von Eschenbach AC, Pathak S. Structural alterations of chromosome 5 in twelve human prostate cancer cell lines. Cancer Genet Cytogenet. 1998 Oct 15; 106(2):105-9. PMID: 9797773.
      View in: PubMed
    243. Logothetis CJ. Emerging strategies in the treatment of testis cancer. Curr Opin Urol. 1998 Sep; 8(5):411-2. PMID: 17039021.
      View in: PubMed
    244. Millikan RE, Logothetis CJ. Prospects for optimized clinical management of bladder cancer by application of phenotypic markers. J Natl Cancer Inst. 1998 Jul 15; 90(14):1028-9. PMID: 9672249.
      View in: PubMed
    245. Tu SM, Pagliaro LC, Banks ME, Amato RJ, Millikan RE, Bugazia NA, Madden T, Newman RA, Logothetis CJ. Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer. Clin Cancer Res. 1998 May; 4(5):1193-201. PMID: 9607577.
      View in: PubMed
    246. Logothetis CJ. Biologic foundation of the therapy for advanced germ cell tumors. Semin Urol Oncol. 1998 May; 16(2):62-4. PMID: 9649228.
      View in: PubMed
    247. Gjertsen BT, Logothetis CJ, McDonnell TJ. Molecular regulation of cell death and therapeutic strategies for cell death induction in prostate carcinoma. Cancer Metastasis Rev. 1998-1999; 17(4):345-51. PMID: 10453278.
      View in: PubMed
    248. Navone NM, Logothetis CJ, von Eschenbach AC, Troncoso P. Model systems of prostate cancer: uses and limitations. Cancer Metastasis Rev. 1998-1999; 17(4):361-71. PMID: 10453280.
      View in: PubMed
    249. Ellerhorst JA, Tu SM, Amato RJ, Finn L, Millikan RE, Pagliaro LC, Jackson A, Logothetis CJ. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2371-6. PMID: 9815636.
      View in: PubMed
    250. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2493-500. PMID: 9815652.
      View in: PubMed
    251. Ellerhorst JA, Sella A, Amato RJ, Tu SM, Millikan RE, Finn LD, Banks M, Logothetis CJ. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer. 1997 Dec 1; 80(11):2128-32. PMID: 9392335.
      View in: PubMed
    252. Millikan R, Logothetis C. Update of the NCCN guidelines for treatment of prostate cancer. Oncology (Williston Park). 1997 Nov; 11(11A):180-93. PMID: 9430189.
      View in: PubMed
    253. Hu SX, Ji W, Zhou Y, Logothetis C, Xu HJ. Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor alpha gene expression. Cancer Res. 1997 Aug 15; 57(16):3339-43. PMID: 9269991.
      View in: PubMed
    254. Chaturvedi V, Li L, Hodges S, Johnston D, Ro JY, Logothetis C, von Eschenbach AC, Batsakis JG, Czerniak B. Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia. Oncogene. 1997 May 1; 14(17):2059-70. PMID: 9160886.
      View in: PubMed
    255. McDonnell TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von Eschenbach AC, Brisbay S, Logothetis CJ. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol. 1997 Feb; 157(2):569-74. PMID: 8996359.
      View in: PubMed
    256. Corral DA, Logothetis CJ. New approaches in the treatment of metastatic transitional-cell cancer of the bladder. World J Urol. 1997; 15(2):139-43. PMID: 9144905.
      View in: PubMed
    257. Sim SJ, Glassman AB, Ro JY, Lee JJ, Logothetis CJ, Liu FJ. Serum calcitonin in small cell carcinoma of the prostate. Ann Clin Lab Sci. 1996 Nov-Dec; 26(6):487-95. PMID: 8908318.
      View in: PubMed
    258. Baker LH, Hanks G, Gershenson D, Kantoff P, Lange P, Logothetis C, Sandler H, Walsh P. NCCN Prostate Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996 Nov; 10(11 Suppl):265-88. PMID: 8953609.
      View in: PubMed
    259. Tu SM, Delpassand ES, Jones D, Amato RJ, Ellerhorst J, Logothetis CJ. Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer. Urol Oncol. 1996 Nov-Dec; 2(6):191-7. PMID: 21224168.
      View in: PubMed
    260. Hutter RV, Montie JE, Busch C, Crignon DJ, Lieber M, Logothetis C, Ragde H, Reuter VE. Current prognostic factors and their relevance to staging. Cancer. 1996 Jul 15; 78(2):369-71. PMID: 8674020.
      View in: PubMed
    261. Logothetis C, Swanson D, Amato R, Banks M, Finn L, Ayala A, Ro J, Babaian R, Dinney C, Ellerhorst J, Hall C, von Eschenbach A. Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma. J Urol. 1996 Apr; 155(4):1241-5. PMID: 8632540.
      View in: PubMed
    262. Amato RJ, Ellerhorst J, Finn L, Logothetis CJ. Absence of antitumor activity with prednisone in patients with progressive androgen-independent prostate carcinoma. Urol Oncol. 1996 Mar-Apr; 2(2):70-3. PMID: 21224139.
      View in: PubMed
    263. Herrada J, Dieringer P, Logothetis CJ. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. J Urol. 1996 Feb; 155(2):620-3. PMID: 8558675.
      View in: PubMed
    264. Amato RJ, Ellerhorst J, Banks M, Logothetis CJ. Carboplatin and ifosfamide and selective consolidation in advanced seminoma. Eur J Cancer. 1995 Dec; 31A(13-14):2223-8. PMID: 8652247.
      View in: PubMed
    265. Amato R, Meyers C, Ellerhorst J, Finn L, Kilbourn R, Sella A, Logothetis C. A phase I trial of intermittent high-dose alpha-interferon and dexamethasone in metastatic renal cell carcinoma. Ann Oncol. 1995 Nov; 6(9):911-4. PMID: 8624294.
      View in: PubMed
    266. Hoosein N, Abdul M, McCabe R, Gero E, Deftos L, Banks M, Hodges S, Finn L, Logothetis C. Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer. Urol Oncol. 1995 Nov-Dec; 1(6):246-51. PMID: 21224126.
      View in: PubMed
    267. Tu SM, Hossan E, Amato R, Kilbourn R, Logothetis CJ. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol. 1995 Nov; 154(5):1719-22. PMID: 7563331.
      View in: PubMed
    268. Nazario A, Amato RJ, Hutchinson L, Bui C, Ellerhorst J, Logothetis CJ. Paclitaxel in extensively pretreated nonseminomatous germ cell tumors. Urol Oncol. 1995 Sep-Oct; 1(5):184-7. PMID: 21224115.
      View in: PubMed
    269. Logothetis CJ, Finn LD, Smith T, Kilbourn RG, Ellerhorst JA, Zukiwski AA, Sella A, Tu SM, Amato RJ. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol. 1995 Sep; 13(9):2272-7. PMID: 7666085.
      View in: PubMed
    270. Hoosein NM, Martin KJ, Abdul M, Logothetis CJ, Kaddurah-Daouk R. Antiproliferative effects of cyclocreatine on human prostatic carcinoma cells. Anticancer Res. 1995 Jul-Aug; 15(4):1339-42. PMID: 7654018.
      View in: PubMed
    271. Abdul M, Logothetis CJ, Hoosein NM. Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol. 1995 Jul; 154(1):247-50. PMID: 7776439.
      View in: PubMed
    272. Tu SM, Robinson ED, Amato RJ, Ellerhorst JA, Kilbourn RG, Logothetis CJ. A phase I study of FAP (5-Fluorouracil, ?-interferon and cisplatin) combined with methotrexate for the treatment of advanced urothelial malignancies. Urol Oncol. 1995 Jul-Aug; 1(4):156-60. PMID: 21224110.
      View in: PubMed
    273. Amato RJ, Ellerhorst J, Bui C, Logothetis CJ. Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate. Urol Oncol. 1995 Jul-Aug; 1(4):168-72. PMID: 21224113.
      View in: PubMed
    274. Sternberg CN, Raghaven D, Ohi Y, Bajorin D, Herr H, Kato T, Kuroda M, Logothetis CH, Scher H, Splinter TA. Neoadjuvant and adjuvant chemotherapy in advanced disease--what are the effects on survival and prognosis? Int J Urol. 1995 Jun; 2 Suppl 2:76-88. PMID: 7553308.
      View in: PubMed
    275. Kilbourn RG, Fonseca GA, Griffith OW, Ewer M, Price K, Striegel A, Jones E, Logothetis CJ. NG-methyl-L-arginine, an inhibitor of nitric oxide synthase, reverses interleukin-2-induced hypotension. Crit Care Med. 1995 Jun; 23(6):1018-24. PMID: 7774211.
      View in: PubMed
    276. Daliani DD, Eisenberg PD, Weems J, Lord R, Fueger R, Logothetis CJ. The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer. J Urol. 1995 May; 153(5):1587-91. PMID: 7536271.
      View in: PubMed
    277. Fornage BD, Logothetis CJ, Swanson DA, Ro JY. Bilateral testicular metastases from prostate carcinoma: gray-scale and color Doppler sonographic findings. J Ultrasound Med. 1995 Mar; 14(3):247-9. PMID: 7760471.
      View in: PubMed
    278. Hsieh JT, Wu HC, Wang Y, Song WT, Li W, Finn L, Logothetis CJ. Evidence for the existence of an organ specific, androgen-independent pathway of progression in patients with metastatic prostate cancer. Urol Oncol. 1995 Mar-Apr; 1(2):67-72. PMID: 21224094.
      View in: PubMed
    279. Abdul M, Hsieh JT, Logothetis CJ, Hoosein NM. Secretion of prostate-specific antigen-suppressing activity by two human prostate carcinoma cell lines. Urol Oncol. 1995 Jan-Feb; 1(1):38-41. PMID: 21224088.
      View in: PubMed
    280. Sella A, Aggarwal BB, Kilbourn RG, Bui CA, Zukiwski AA, Logothetis CJ. Phase I study of tumor necrosis factor plus actinomycin D in patients with androgen-independent prostate cancer. Cancer Biother. 1995; 10(3):225-35. PMID: 8547961.
      View in: PubMed
    281. Logothetis CJ, Hossan EA, Smith TL. SMS 201-995 in the treatment of refractory prostatic carcinoma. Anticancer Res. 1994 Nov-Dec; 14(6B):2731-4. PMID: 7872709.
      View in: PubMed
    282. Crawford ED, Kozlowski JM, Debruyne FM, Fair WR, Logothetis CJ, Balmer C, Robinson RG, Porter AT, Kirk D. The use of strontium 89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer. Urology. 1994 Oct; 44(4):481-5. PMID: 7524233.
      View in: PubMed
    283. Logothetis CJ, Hoosein NM, Hsieh JT. The clinical and biological study of androgen independent prostate cancer (AI PCa). Semin Oncol. 1994 Oct; 21(5):620-9. PMID: 7524155.
      View in: PubMed
    284. Mitropoulos D, Dimopoulos MA, Kiroudi-Voulgari A, Zervas A, Dimopoulos C, Logothetis CJ. Neoadjuvant cisplatin and interferon-alpha 2B in the treatment and organ preservation of penile carcinoma. J Urol. 1994 Oct; 152(4):1124-6. PMID: 8072080.
      View in: PubMed
    285. Ellerhorst JA, Kilbourn RG, Amato RJ, Zukiwski AA, Jones E, Logothetis CJ. Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma. J Urol. 1994 Sep; 152(3):841-5. PMID: 8051732.
      View in: PubMed
    286. Logothetis CJ, Hossan E, Recondo G, Sella A, Ellerhorst J, Kilbourn R, Zukiwski A, Amato R. 5-Fluorouracil and interferon-alpha in chemotherapy refractory bladder carcinoma: an effective regimen. Anticancer Res. 1994 May-Jun; 14(3B):1265-9. PMID: 8067694.
      View in: PubMed
    287. Abdul M, Anezinis PE, Logothetis CJ, Hoosein NM. Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists. Anticancer Res. 1994 May-Jun; 14(3A):1215-20. PMID: 8074475.
      View in: PubMed
    288. Sella A, Kilbourn R, Amato R, Bui C, Zukiwski AA, Ellerhorst J, Logothetis CJ. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol. 1994 Apr; 12(4):683-8. PMID: 7512126.
      View in: PubMed
    289. Dimopoulos MA, Finn L, Logothetis CJ. Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy. J Urol. 1994 Mar; 151(3):598-600; discussion 600-1. PMID: 8308966.
      View in: PubMed
    290. Sella A, Kilbourn RG, Gray I, Finn L, Zukiwski AA, Ellerhorst J, Amato RJ, Logothetis CJ. Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer. Cancer Biother. 1994; 9(2):103-11. PMID: 7812360.
      View in: PubMed
    291. Hoosein NM, Logothetis CJ, Chung LW. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. J Urol. 1993 May; 149(5):1209-13. PMID: 8097794.
      View in: PubMed
    292. Dimopoulos MA, Logothetis CJ, Markowitz A, Sella A, Amato R, Ro J. Collecting duct carcinoma of the kidney. Br J Urol. 1993 Apr; 71(4):388-91. PMID: 8499979.
      View in: PubMed
    293. Sella A, Swanson DA, Ro JY, Putnam JB, Amato RJ, Markowitz AB, Logothetis CJ. Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma. J Urol. 1993 Jan; 149(1):19-21; discussion 21-2. PMID: 8417208.
      View in: PubMed
    294. Deisseroth AB, Hanania EG, Fu S, Claxton D, Andreeff M, Champlin R, Kavanagh J, Hortobagyi G, Holmes F, Reading C, et al. Genetic therapy of human neoplastic disease. J Hematother. 1993; 2(3):373-5. PMID: 7921999.
      View in: PubMed
    295. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992 Dec 15; 52(24):6940-4. PMID: 1458483.
      View in: PubMed
    296. Logothetis CJ, Amato RJ. Dose intensity in germ cell tumors: lessons learned? J Natl Cancer Inst. 1992 Nov 18; 84(22):1686-7. PMID: 1331481.
      View in: PubMed
    297. Logothetis C. Treatment of chemotherapy-refractory metastatic urothelial tumors. Urol Clin North Am. 1992 Nov; 19(4):775-7. PMID: 1441031.
      View in: PubMed
    298. Logothetis CJ, Xu HJ, Ro JY, Hu SX, Sahin A, Ordonez N, Benedict WF. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst. 1992 Aug 19; 84(16):1256-61. PMID: 1640485.
      View in: PubMed
    299. Amato RJ, Logothetis CJ, Hallinan R, Ro JY, Sella A, Dexeus FH. Chemotherapy for small cell carcinoma of prostatic origin. J Urol. 1992 Mar; 147(3 Pt 2):935-7. PMID: 1311396.
      View in: PubMed
    300. Sella A, Logothetis CJ, Fitz K, Dexeus FH, Amato R, Kilbourn R, Wallace S. Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer. J Urol. 1992 Mar; 147(3):573-7. PMID: 1538431.
      View in: PubMed
    301. Giralt SA, Dexeus F, Amato R, Sella A, Logothetis C. Hyperthyroidism in men with germ cell tumors and high levels of beta-human chorionic gonadotropin. Cancer. 1992 Mar 1; 69(5):1286-90. PMID: 1371235.
      View in: PubMed
    302. Grignon DJ, Ro JY, Ayala AG, Shum DT, Ordóñez NG, Logothetis CJ, Johnson DE, Mackay B. Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 22 cases. Cancer. 1992 Jan 15; 69(2):527-36. PMID: 1309435.
      View in: PubMed
    303. Logothetis CJ. Chemotherapy resistant transitional cell carcinoma as a target for chemoprevention. J Cell Biochem Suppl. 1992; 16I:128-31. PMID: 1305675.
      View in: PubMed
    304. Chung LW, Li W, Gleave ME, Hsieh JT, Wu HC, Sikes RA, Zhau HE, Bandyk MG, Logothetis CJ, Rubin JS, et al. Human prostate cancer model: roles of growth factors and extracellular matrices. J Cell Biochem Suppl. 1992; 16H:99-105. PMID: 1289680.
      View in: PubMed
    305. Wishnow KI, Levinson AK, Johnson DE, Tenney DM, Grignon DJ, Ro JY, Ayala AJ, Logothetis CJ, Swanson DA, Babaian RJ, et al. Stage B (P2/3A/N0) transitional cell carcinoma of bladder highly curable by radical cystectomy. Urology. 1992 Jan; 39(1):12-6. PMID: 1728789.
      View in: PubMed
    306. Logothetis C, Hoosein N. The inhibition of the paracrine progression of prostate cancer as an approach to early therapy of prostatic carcinoma. J Cell Biochem Suppl. 1992; 16H:128-34. PMID: 1337763.
      View in: PubMed
    307. Dexeus FH, Logothetis CJ, Sella A, Amato R, Kilbourn R, Fitz K, Striegel A. Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. J Urol. 1991 Nov; 146(5):1284-7. PMID: 1719241.
      View in: PubMed
    308. Dimopoulos MA, Amato RJ, Logothetis CJ. Predictive factors for effective salvage therapy of nonseminomatous germ cell tumors of testis. Urology. 1991 Oct; 38(4):351-4. PMID: 1661457.
      View in: PubMed
    309. Sella A, el Naggar A, Ro JY, Dexeus FH, Amato RJ, Lee JS, Finn L, Logothetis CJ. Evidence of malignant features in histologically mature teratoma. J Urol. 1991 Oct; 146(4):1025-8. PMID: 1680200.
      View in: PubMed
    310. Dexeus FH, Logothetis CJ, Sella A, Amato R, Kilbourn R, Ogden S, Striegel A, Kwan J, Newman RA. Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. J Urol. 1991 Sep; 146(3):709-13. PMID: 1831513.
      View in: PubMed
    311. Logothetis CJ. Organ preservation in bladder carcinoma: a matter of selection. J Clin Oncol. 1991 Sep; 9(9):1525-6. PMID: 1875215.
      View in: PubMed
    312. Dexeus FH, Logothetis CJ, Sella A, Fitz K, Striegel A, Amato RJ, Liu FJ. Serum biomarkers in metastatic renal cell carcinoma. Urology. 1991 Jul; 38(1):6-10. PMID: 1714107.
      View in: PubMed
    313. Sella A, Logothetis CJ, Dexeus FH, Amato R, Finn L, Fitz K. Cisplatin combination chemotherapy for elderly patients with urothelial tumours. Br J Urol. 1991 Jun; 67(6):603-7. PMID: 2070205.
      View in: PubMed
    314. Logothetis CJ, Hossan E, Sella A, Dexeus FH, Amato RJ. Fluorouracil and recombinant human interferon alfa-2a in the treatment of metastatic chemotherapy-refractory urothelial tumors. J Natl Cancer Inst. 1991 Feb 20; 83(4):285-8. PMID: 1994058.
      View in: PubMed
    315. Dexeus FH, Kilbourn R, Chong C, Logothetis CJ, Sella A, Grignon D. Association of germ cell tumors and Hodgkin's disease. Urology. 1991 Feb; 37(2):129-34. PMID: 1846990.
      View in: PubMed
    316. Sella A, Logothetis CJ, Dexeus FH, Amato R. Chemotherapy immediately after surgery for patients with germ cell tumors. Urology. 1990 Sep; 36(3):264-6. PMID: 2168105.
      View in: PubMed
    317. Gutterman J, Vadhan-Raj S, Logothetis C, Anaissle E, Estey E, Talpaz M, Kurzrock R. Effects of granulocyte-macrophage colony-stimulating factor in iatrogenic myelosuppression, bone marrow failure, and regulation of host defense. Semin Hematol. 1990 Jul; 27(3 Suppl 3):15-24. PMID: 2198660.
      View in: PubMed
    318. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, Kilbourn RG. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990 Jun; 8(6):1050-5. PMID: 2189954.
      View in: PubMed
    319. Logothetis CJ, Dexeus FH, Sella A, Amato RJ, Kilbourn RG, Finn L, Gutterman JU. Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor. J Natl Cancer Inst. 1990 Apr 18; 82(8):667-72. PMID: 2181151.
      View in: PubMed
    320. Dexeus FH, Logothetis CJ, Sella A, Fitz K, Amato R, Reuben JM, Dozier N. Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma. J Clin Oncol. 1990 Feb; 8(2):325-9. PMID: 2137163.
      View in: PubMed
    321. Logothetis CJ. The case for relevant staging of germ cell tumors. Cancer. 1990 Feb 1; 65(3 Suppl):709-17. PMID: 2154316.
      View in: PubMed
    322. Logothetis CJ, Dexeus FH, Chong C, Sella A, Ogden S. The impact of chemotherapy on the survival of patients with metastatic urothelial tumors. Prog Clin Biol Res. 1990; 350:107-14. PMID: 2201037.
      View in: PubMed
    323. Logothetis CJ, Chong C, Dexeus FH, Sella A, Ogden S. Intensive chemotherapy for metastatic nonseminomatous germ cell tumors. Prog Clin Biol Res. 1990; 350:301-7. PMID: 1696741.
      View in: PubMed
    324. Dexeus FH, Logothetis CJ, Sella A, Finn L. Interferon alternating with chemotherapy for patients with metastatic renal cell carcinoma. Am J Clin Oncol. 1989 Aug; 12(4):350-4. PMID: 2667326.
      View in: PubMed
    325. Sella A, Logothetis CJ, Dexeus FH, Amato R. Pulmonary air cyst associated with combination chemotherapy containing bleomycin. AJR Am J Roentgenol. 1989 Jul; 153(1):191. PMID: 2472057.
      View in: PubMed
    326. Sella A, Dexeus FH, Chong C, Ro JY, Logothetis CJ. Radiation therapy-associated invasive bladder tumors. Urology. 1989 Mar; 33(3):185-8. PMID: 2919477.
      View in: PubMed
    327. Têtu B, Ro JY, Ayala AG, Ordóñez NG, Logothetis CJ, von Eschenbach AC. Small cell carcinoma of prostate associated with myasthenic (Eaton-Lambert) syndrome. Urology. 1989 Feb; 33(2):148-52. PMID: 2536972.
      View in: PubMed
    328. Logothetis CJ, Dexeus FH, Chong C, Sella A, Ayala AG, Ro JY, Pilat S. Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience. J Urol. 1989 Jan; 141(1):33-7. PMID: 2908950.
      View in: PubMed
    329. Dexeus FH, Shirkhoda A, Logothetis CJ, Chong C, Sella A, Ogden S, Swanson D. Clinical and radiological correlation of retroperitoneal metastasis from nonseminomatous testicular cancer treated with chemotherapy. Eur J Cancer Clin Oncol. 1989 Jan; 25(1):35-43. PMID: 2920767.
      View in: PubMed
    330. Shirkhoda A, Dexeus FH, Logothetis CJ. Clinical and radiologic staging of locally advanced and inoperable bladder carcinoma. J Comput Tomogr. 1988 Oct; 12(4):298-302. PMID: 3197433.
      View in: PubMed
    331. Logothetis CJ, Johnson DE, Chong C, Dexeus FH, Sella A, Ogden S, Smith T, Swanson DA, Babaian RJ, Wishnow KI, et al. Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol. 1988 Oct; 6(10):1590-6. PMID: 3171626.
      View in: PubMed
    332. Dunphy CH, Ayala AG, Swanson DA, Ro JY, Logothetis C. Clinical stage I nonseminomatous and mixed germ cell tumors of the testis. A clinicopathologic study of 93 patients on a surveillance protocol after orchiectomy alone. Cancer. 1988 Sep 15; 62(6):1202-6. PMID: 2842034.
      View in: PubMed
    333. Chong CD, Logothetis CJ, Savaraj N, Fritsche HA, Gietner AM, Samuels ML. The correlation of vinblastine pharmacokinetics to toxicity in testicular cancer patients. J Clin Pharmacol. 1988 Aug; 28(8):714-8. PMID: 3216038.
      View in: PubMed
    334. Logothetis CJ. Adjuvant chemotherapy for testicular cancer. N Engl J Med. 1988 Jul 7; 319(1):53. PMID: 2837667.
      View in: PubMed
    335. Dexeus FH, Logothetis CJ, Chong C, Sella A, Ogden S. Genetic abnormalities in men with germ cell tumors. J Urol. 1988 Jul; 140(1):80-4. PMID: 2837589.
      View in: PubMed
    336. Logothetis CJ, Johnson DE, Chong C, Dexeus FH, Ogden S, von Eschenbach A, Ayala A. Adjuvant chemotherapy of bladder cancer: a preliminary report. J Urol. 1988 Jun; 139(6):1207-11. PMID: 3373589.
      View in: PubMed
    337. Chong CD, Logothetis CJ, von Eschenbach AC, Ayala AG, Samuels ML. Successful treatment of pure endodermal sinus tumors in adult men. J Clin Oncol. 1988 Feb; 6(2):303-7. PMID: 2448426.
      View in: PubMed
    338. Floyd C, Ayala AG, Logothetis CJ, Silva EG. Spermatocytic seminoma with associated sarcoma of the testis. Cancer. 1988 Jan 15; 61(2):409-14. PMID: 3334976.
      View in: PubMed
    339. Logothetis CJ. Carcinoma-in-situ of the testis. Lancet. 1987 Oct 24; 2(8565):977. PMID: 2889904.
      View in: PubMed
    340. Logothetis CJ, Samuels ML, Ogden SL, Dexeus FH, Chong CD. Cyclophosphamide and sequential cisplatin for advanced seminoma: long-term followup in 52 patients. J Urol. 1987 Oct; 138(4):789-94. PMID: 3656535.
      View in: PubMed
    341. Sella A, Logothetis CJ, Ro JY, Swanson DA, Samuels ML. Sarcomatoid renal cell carcinoma. A treatable entity. Cancer. 1987 Sep 15; 60(6):1313-8. PMID: 2441841.
      View in: PubMed
    342. Logothetis CJ. Have aggressive chemotherapy regimens improved results in advanced germ cell tumors. Eur J Cancer Clin Oncol. 1987 Sep; 23(9):1415-6. PMID: 2445581.
      View in: PubMed
    343. Logothetis CJ, Swanson DA, Dexeus F, Chong C, Ogden S, Ayala AG, von Eschenbach AC, Johnson DE, Samuels ML. Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients. J Clin Oncol. 1987 Jun; 5(6):906-11. PMID: 2438389.
      View in: PubMed
    344. Têtu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, Ordonez NG. Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer. 1987 May 15; 59(10):1803-9. PMID: 3030528.
      View in: PubMed
    345. Dexeus FH, Logothetis CJ, Samuels ML, Ayala AG, Hossan E. Complete responses in metastatic transitional cell carcinoma of the prostate with cisplatin regimens. J Urol. 1987 Jan; 137(1):122-5. PMID: 3795354.
      View in: PubMed
    346. Chong C, Logothetis CJ, von Eschenbach A, Ayala A, Samuels M. Orchiectomy in advanced germ cell cancer following intensive chemotherapy: a comparison of systemic to testicular response. J Urol. 1986 Dec; 136(6):1221-3. PMID: 3022018.
      View in: PubMed
    347. Dexeus FH, Logothetis C, Samuels ML, Hossan B. Phase II study of spirogermanium in metastatic prostate cancer. Cancer Treat Rep. 1986 Sep; 70(9):1129-30. PMID: 3742495.
      View in: PubMed
    348. Dexeus F, Logothetis C, Hossan E, Samuels ML. Carcinoembryonic antigen and beta-human chorionic gonadotropin as serum markers for advanced urothelial malignancies. J Urol. 1986 Aug; 136(2):403-7. PMID: 2426474.
      View in: PubMed
    349. Logothetis CJ, Samuels ML. Prognostic factors in disseminated germ cell tumors. J Clin Oncol. 1986 Aug; 4(8):1278-80. PMID: 3016207.
      View in: PubMed
    350. Logothetis CJ, Samuels ML, Selig DE, Ogden S, Dexeus F, Swanson D, Johnson D, von Eschenbach A. Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients. Am J Med. 1986 Aug; 81(2):219-28. PMID: 2426944.
      View in: PubMed
    351. Logothetis CJ, Samuels ML, Selig DE, Johnson DE, Swanson DA, von Eschenbach AC. Primary chemotherapy followed by a selective retroperitoneal lymphadenectomy in the management of clinical stage II testicular carcinoma: a preliminary report. J Urol. 1985 Dec; 134(6):1127-30. PMID: 2414470.
      View in: PubMed
    352. Logothetis CJ, Samuels ML, Ogden S. Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C. Urology. 1985 Sep; 26(3):252-5. PMID: 3929441.
      View in: PubMed
    353. Logothetis CJ, Samuels ML, Ogden S, Dexeus FH, Swanson D, Johnson DE, von Eschenbach A. Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases. J Urol. 1985 Sep; 134(3):460-4. PMID: 2993671.
      View in: PubMed
    354. Logothetis CJ. Endodermal sinus tumors. Chest. 1985 Jul; 88(1):6-7. PMID: 2408823.
      View in: PubMed
    355. Dexeus F, Logothetis CJ, Samuels ML, Hossan E, von Eschenbach AC. Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer. Cancer Treat Rep. 1985 Jul-Aug; 69(7-8):885-6. PMID: 4016795.
      View in: PubMed
    356. Logothetis CJ, Samuels ML, Selig DE, Dexeus FH, Johnson DE, Swanson DA, von Eschenbach AC. Chemotherapy of extragonadal germ cell tumors. J Clin Oncol. 1985 Mar; 3(3):316-25. PMID: 2579212.
      View in: PubMed
    357. Logothetis CJ, Newell GR, Samuels ML. Testicular cancer in homosexual men with cellular immune deficiency: report of 2 cases. J Urol. 1985 Mar; 133(3):484-6. PMID: 2579253.
      View in: PubMed
    358. Logothetis CJ, Samuels ML, Selig D, Swanson D, Johnson DE, von Eschenbach AC. Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis. J Clin Oncol. 1985 Mar; 3(3):326-35. PMID: 2579213.
      View in: PubMed
    359. Logothetis CJ. Preoperative chemotherapy in the treatment of germinal tumors. Prog Clin Biol Res. 1985; 201:341-50. PMID: 2419920.
      View in: PubMed
    360. Logothetis CJ, Samuels ML, Selig DE, Wallace S, Johnson DE. Combined intravenous and intra-arterial cyclophosphamide, doxorubicin, and cisplatin (CISCA) in the management of select patients with invasive urothelial tumors. Cancer Treat Rep. 1985 Jan; 69(1):33-8. PMID: 2981619.
      View in: PubMed
    361. Logothetis CJ. Perioperative chemotherapy for the management of primary local regional urothelial tumors. Prog Clin Biol Res. 1985; 201:359-66. PMID: 3841594.
      View in: PubMed
    362. Rusch VW, Logothetis C, Samuels M. Endodermal sinus tumor of the mediastinum. Report of apparent cure in two patients with extensive disease. Chest. 1984 Nov; 86(5):745-7. PMID: 6207993.
      View in: PubMed
    363. Logothetis CJ, Samuels ML. Surgery in the management of stage III germinal cell tumors. Observations on the M.D. Anderson Hospital experience, 1971-1979. Cancer Treat Rev. 1984 Mar; 11(1):27-37. PMID: 6203643.
      View in: PubMed
    364. Logothetis CJ, Samuels ML, Trindade A, Grant C, Gomez L, Ayala A. The prognostic significance of endodermal sinus tumor histology among patients treated for stage III nonseminomatous germ cell tumors of the testes. Cancer. 1984 Jan 1; 53(1):122-8. PMID: 6317156.
      View in: PubMed
    365. Logothetis CJ, Samuels ML, von Eschenbach AC, Trindade A, Ogden S, Grant C, Johnson DE. Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J Clin Oncol. 1983 Jun; 1(6):368-79. PMID: 6422006.
      View in: PubMed
    366. Bracken RB, Johnson DE, Frazier OH, Logothetis CJ, Trindade A, Samuels ML. The role of surgery following chemotherapy in stage III germ cell neoplasms. J Urol. 1983 Jan; 129(1):39-43. PMID: 6298475.
      View in: PubMed
    367. Libshitz HI, Jing BS, Wallace S, Logothetis CJ. Sterilized metastases: a diagnostic and therapeutic dilemma. AJR Am J Roentgenol. 1983 Jan; 140(1):15-9. PMID: 6600307.
      View in: PubMed
    368. Logothetis CJ, Samuels ML, Trindade A, Johnson DE. The growing teratoma syndrome. Cancer. 1982 Oct 15; 50(8):1629-35. PMID: 6288220.
      View in: PubMed
    369. Logothetis CJ, Samuels ML, Wallace S, Chuang V, Trindade A, Grant C, Haynie TP, Johnson DE. Management of pelvic complications of malignant urothelial tumors with combined intra-arterial and iv chemotherapy. Cancer Treat Rep. 1982 Jul; 66(7):1501-7. PMID: 7046931.
      View in: PubMed
    370. Logothetis CJ, von Eschenbach AC, Samuels ML, Trindade A, Johnson DE. Doxorubicin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: a preliminary report. Cancer Treat Rep. 1982 Jan; 66(1):57-63. PMID: 7053267.
      View in: PubMed
    371. Logothetis CJ, Samuels ML, Trindade A. The management of brain metastases in germ cell tumors. Cancer. 1982 Jan 1; 49(1):12-8. PMID: 6274499.
      View in: PubMed
    372. Trindade A, Samuels ML, Logothetis CJ. Chemotherapy of carcinoma of renal pelvis: preliminary report. Urology. 1981 Jul; 18(1):54-9. PMID: 6894814.
      View in: PubMed
    373. Poitevin R, Poitevin J, Defous A, Llanes-Llanes F, Logothetis C. [Periodontolysis and selective grinding]. Rev Stomatol Chir Maxillofac. 1971 Apr-May; 72(3):453-62. PMID: 5285441.
      View in: PubMed
    374. Logothetis C, Westlake WE. The role of the Food and Agriculture Organization of the United Nations in the pesticide residue problem. Residue Rev. 1964; 7:1-8. PMID: 5879416.
      View in: PubMed
    375. LOGOTHETIS C, SPURRIER WA, GREENSPAN I, SCHOOLMAN HM, SCHWARTZ SO. Studies in leukemia. XIV. Effect of human serum on development of leukemia in AKR mice. Proc Soc Exp Biol Med. 1960 Feb; 103:420-1. PMID: 14417976.
      View in: PubMed
    376. Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer. Urologic Oncology. 6:111-115.
    377. Intra-arterial chemotherapy for malignant urothelial tumors. Cancer Bulletin. 36:47-52.
    378. Session II. Cancer Immunology, Immunotherapy. 52.
    379. The Molecular Taxonomy of Primary Prostate Cancer. Cell. 163:1011-1025.
    380. Human prostate cancer model. Journal of Cellular Biochemistry. 50:99-105.
    381. Docetaxel in the treatment of prostate cancer. Seminars in Oncology. 28:1-2.
    382. Sequential chemotherapy with cytoxan, adriamycin, and cis-platinum alternating with velban-bleomycin for stage III germinal cancer with poor prognosis. 552.
    383. Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancer. Oncotarget. 6:41988-41996.
    384. Intraprostatic AD-p53 gene therapy followed by radical prostatectomy. Prostate Cancer and Prostatic Diseases. 2.
    385. Is it time to re-examine the prostate cancer treatment paradigm by targeting the interaction between the prostate and metastases?. Journal of Clinical Oncology. 34:2810-2811.
    386. Targeted molecular-genetic imaging and liganddirected therapy in aggressive variant prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 113:12786-12791.
    387. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 7:86280-86289.
    388. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proceedings of the National Academy of Sciences of the United States of America. 113:11919-11924.
    389. Posttranslational regulation of Akt in human cancer. Cell and Bioscience. 4.
    390. Secretion of prostate-specific antigen-suppressing activity by two human prostate carcinoma cell lines. Urologic Oncology: Seminars and Original Investigations. 1:38-41.
    391. Trial design and objectives for castration-resistant prostate cancer. Journal of Clinical Oncology. 34:1402-1418.
    392. Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. Neoplasia (United States). 18:1-9.
    393. Management of patients with advanced prostate cancer. Annals of Oncology. 26:1589-1604.
    394. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine.
    395. Anti-CTLA-4 therapy in bladder cancer patients alters immune responses by increasing IFNγ production and decreasing the CD4+FOXP3 + regulatory T cells in the tumor microenvironment. Review of Clinical Pharmacology and Pharmacokinetics, International Edition. 22:217-220.
    396. Evidence for the existence of an organ specific, androgen-independent pathway of progression in patients with metastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations. 1:67-72.
    397. Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties. Oncogene.
    398. The inhibition of the paracrine progression of prostate cancer as an approach to early therapy of prostatic carcinoma. Journal of Cellular Biochemistry. 50:128-134.
    399. Chemotherapeutic approaches in advanced prostate cancer. Oncology. 8:15-18.
    400. The pattern of serum markers in patients with androgen-independent adenocarcinoma of the prostate. Urologic Oncology. 5:97-103.
    401. Cancer of the testis.
    402. Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance. Carcinogenesis. 37:965-971.
    403. In reply. Journal of Clinical Oncology. 26:4051.
    404. Estramustine in combination with vinblastine and mitomycin-C for patients with progressive androgen independent adenocarcinoma of the prostate. Prostate Cancer and Prostatic Diseases. 2:83-87.
    405. Seminars in urologic oncology. Seminars in Urologic Oncology. 16:61.
    406. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget. 7:46321-46334.
    407. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. Journal of Clinical Oncology. 35:40-47.
    408. Integrating murine and clinical trials with cabozantinib to understand roles of MET and VEGFR2 as targets for growth inhibition of prostate cancer. Clinical Cancer Research. 22:107-121.
    409. Response. Journal of the National Cancer Institute. 100:682-683.
    410. Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Clinical Cancer Research. 21:1621-1627.
    411. Identification of bone-derived factors conferring de novo therapeutic resistance in metastatic prostate cancer. Cancer Research. 75:4949-4959.
    412. Response. Journal of the National Cancer Institute. 104:717.
    413. DMF regimen for hormone-refractory adenocarcinoma of the prostate. The first 42 patients. Cancer Bulletin. 34:26-28.
    414. Focus on TILs. Cancer Immunity. 7.
    415. Reply to G. Colloca. Journal of Clinical Oncology. 30:3562.
    416. Erratum. Science Translational Medicine. 7.
    417. Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer. Prostate Cancer and Prostatic Diseases. 18:276-280.
    418. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer. Scientific Reports. 6.
    419. CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. Nature Communications. 7.
    420. Significance of neuroendocrine differentiation in prostatic carcinoma. Cancer Journal. 9:291-295.
    421. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). European Urology. 66:815-825.
    422. The Reply. The American Journal of Medicine. 82:576.
    423. Peak vinblastine concentration as a montior of non hematologic toxicity in patients with testicular cancer.
    424. Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. Clinical Cancer Research. 22:1520-1530.
    425. A phase I study of FAP (5-Fluorouracil, α-interferon and cisplatin) combined with methotrexate for the treatment of advanced urothelial malignancies. Urologic Oncology: Seminars and Original Investigations. 1:156-160.
    426. The role of chemotherapy in the management of urothelial tumors. World Journal of Urology. 6:163-166.
    427. Results of therapy of 119 stage I and stage II adjuvant testicular cancer patients. 630.
    428. Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. BJU International. 117:469-477.
    429. Intratumoral heterogeneity. Cancer.
    430. Introduction. Seminars in Oncology. 26:139.
    431. Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity. Cancer Biology and Therapy. 8:241-248.
    432. Doxorubicin, mitomycin-C, 5-fluorouracil (DMF) in the therapy of hormonal resistant adenocarcinoma of the prostate.
    433. Adriamycin programs and the sarcomatous variant of renal cell carcinoma.
    434. Update of cyclic chemotherapy in 100 patients (pts) with advanced nonseminomatous germ cell tumors (NSGCT).
    435. Gene therapy. Cancer Bulletin. 45:139-145.
    436. Concluding comments. Seminars in Oncology. 26:68.
    437. Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate. Urologic Oncology: Seminars and Original Investigations. 1:168-172.
    438. Clinical Challenges for Treatment and a Cure. 155-167.
    439. Intermittent low-dose IFN gamma treatment for metastatic renal cell carcinoma. Onkologie. 18:339-345.
    440. Paclitaxel in extensively pretreated nonseminomatous germ cell tumors. Urologic Oncology: Seminars and Original Investigations. 1:184-187.
    441. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Journal of Urology. 175:1365-1366.
    442. The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study. BMC Cancer. 16.
    443. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. Journal of Clinical Oncology. 34:1652-1659.
    444. Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations. 1:246-251.
    445. Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Discovery. 6:80-95.
    LOGOTHETIS's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description